PITTSBURGH--(BUSINESS WIRE)-- A new study reporting an association between ChemoFx® Drug Response Marker results and recurrence free survival (RFS) of cervical cancer patients was presented at the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), held in Vancouver October 13-16, 2012.
The abstract was submitted by Dr. Perry W. Grigsby and titled, In Vitro Chemoresponse Analysis and Clinical Outcomes in Cervical Cancer. The study, performed in collaboration with the Washington University School of Medicine, analyzed 33 patients with stage IIb or IIIb cervical cancer who were treated with weekly cisplatin chemoradiation (chemoRT) and received pre-treatment cisplatin chemoresponse testing with ChemoFx. Results revealed the 2-year recurrence free survivals (RFS) for patients who scored as responsive or intermediately responsive to cisplatin via ChemoFx were 87%, compared to 58% for those who were scored as non-responsive to cisplatin (p = 0.047).
The analysis concluded that the use of ChemoFx to perform a chemoresponse analysis of cervical cancer prior to treatment was feasible and predictive of RFS outcomes in patients treated with weekly cisplatin chemoRT. These results support the use of ChemoFx for helping with treatment decisions for cervical cancer patients.
“In retrospective studies, chemoresponse assays have shown significant correlation between assay prediction of response and progression free interval,” says Dr. Perry W. Grigsby, lead author of the study. “From a clinical standpoint, such tests provide clinicians with more information when choosing an effective second line agent for the patient to receive maximum benefit, which is the ultimate goal when individualizing cancer treatment to each patient.”
About Precision Therapeutics
Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum.
Precision's state of the art Comprehensive Tumor Profiling is an integrated, straightforward approach combining three core platforms of personalized medicine to capture the total sum of genomic, proteomic and functional information for each patient's cancer.
Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. Precision currently receives ChemoFx specimens from 271 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care. To date, approximately 80,000 patient specimens have been submitted for ChemoFx testing using 105 unique chemotherapy treatments and combinations.
Precision Therapeutics Inc.
Pam Ranallo, 412-432-1500 ext. 1502
Source: Precision Therapeutics Inc.